Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03528668 · ClinicalTrials.gov registry record
Patient Receptiveness to Using Virtual Reality
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 89
- Enrollment target
NCT03528668: Completed study, sponsored by Massachusetts General Hospital.
NCT03528668 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 89 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03528668 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 89 participants
- Enrollment target
Study Summary
This study will evaluate the acceptability, use, and general effect that exposure to virtual reality has on hospitalized patients reporting at least one discomfort including recent or current moderate-severe pain.
Primary Outcome
Change in subjective report of pain measured on a visual analog scale
Interventions
- DEVICE Virtual Reality Exposure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2018-04-16 |
| Est. Completion | 2018-10-12 |
What the finished NCT03528668 record still lists
NCT03528668 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 89 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Virtual Reality Exposure is the first listed.
NCT03528668 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03528668 about?
NCT03528668 is a clinical study titled "Patient Receptiveness to Using Virtual Reality". This study will evaluate the acceptability, use, and general effect that exposure to virtual reality has on hospitalized patients reporting at least one discomfort including recent or current moderate-severe pain.
What is the current status of trial NCT03528668?
This trial is currently completed. The enrollment target is 89 participants. The study started on 2018-04-16. Estimated completion is 2018-10-12.
What interventions are being tested in trial NCT03528668?
The interventions under investigation include: Virtual Reality Exposure (DEVICE).
Who is sponsoring clinical trial NCT03528668?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI